ER 50891

CAS No. 187400-85-7

ER 50891( —— )

Catalog No. M33848 CAS No. 187400-85-7

ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 416 In Stock
10MG 549 In Stock
25MG 881 In Stock
50MG 1172 In Stock
100MG 1562 In Stock
200MG 2111 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ER 50891
  • Note
    Research use only, not for human use.
  • Brief Description
    ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.
  • Description
    ER-50891 is a potent antagonist of retinoic acid receptor α(RARα). ER-50891 significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    Retinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    187400-85-7
  • Formula Weight
    432.51
  • Molecular Formula
    C29H24N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C)(C)C=1C2=C(C(=CC(=N2)C=3NC(=CC3)C4=CC=C(C(O)=O)C=C4)C5=CC=CC=C5)C=CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Batran RZ, et al. New quinolone derivatives as neuropeptide S receptor antagonists: Design, synthesis, homology modeling, dynamic simulations and modulation of Gq/Gs signaling pathways. Bioorg Chem. 2021;111:104817.?
molnova catalog
related products
  • Bexarotene

    Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

  • Quisinostat 2HCl

    Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay.

  • CD3254

    CD3254 is a selective and potent retinoid X receptor-like (RXR) agonist that inhibits neuronal cell death with OGD/reoxygenation.